These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 30604193)
1. A Novel Simulation-Based Approach for Comparing the Population Against Average Bioequivalence Statistical Test for the Evaluation of Nasal Spray Products on Spray Pattern and Droplet Size Distribution Parameters. Grmaš J; Lužar-Stiffler V; Dreu R; Injac R AAPS PharmSciTech; 2019 Jan; 20(1):38. PubMed ID: 30604193 [TBL] [Abstract][Full Text] [Related]
2. Cascade Impactor Equivalence Testing: Comparison of the Performance of the Modified Chi-Square Ratio Statistic (mCSRS) with the Original CSRS and EMA's Average Bioequivalence Approach. Kurumaddali A; Christopher D; Sandell D; Strickland H; Morgan B; Bulitta J; Wiggenhorn C; Stein S; Lyapustina S; Hochhaus G AAPS PharmSciTech; 2019 Jul; 20(6):249. PubMed ID: 31286316 [TBL] [Abstract][Full Text] [Related]
3. Analytical Challenges of Spray Pattern Method Development for Purposes of Grmaš J; Dreu R; Injac R J Aerosol Med Pulm Drug Deliv; 2019 Aug; 32(4):200-212. PubMed ID: 30964389 [No Abstract] [Full Text] [Related]
4. Between-Batch Bioequivalence (BBE): a Statistical Test to Evaluate In Vitro Bioequivalence Considering the Between-Batch Variability. Bodin J; Liandrat S; Kocevar G; Petitcolas C AAPS J; 2020 Sep; 22(5):119. PubMed ID: 32910283 [TBL] [Abstract][Full Text] [Related]
5. The influence of actuation parameters on in vitro testing of nasal spray products. Guo C; Doub WH J Pharm Sci; 2006 Sep; 95(9):2029-40. PubMed ID: 16865693 [TBL] [Abstract][Full Text] [Related]
6. Performance of the Population Bioequivalence (PBE) Statistical Test with Impactor Sized Mass Data. Chen S; Morgan B; Beresford H; Burmeister Getz E; Christopher D; Långström G; Strickland H; Wiggenhorn C; Lyapustina S AAPS PharmSciTech; 2019 Aug; 20(7):296. PubMed ID: 31444601 [TBL] [Abstract][Full Text] [Related]
7. Case studies, practical issues and observations on population and individual bioequivalence. Zariffa NM; Patterson SD; Boyle D; Hyneck M Stat Med; 2000 Oct; 19(20):2811-20. PubMed ID: 11033577 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec. Dayal P; Shaik MS; Singh M J Pharm Sci; 2004 Jul; 93(7):1725-42. PubMed ID: 15176062 [TBL] [Abstract][Full Text] [Related]
9. Elucidation of Formulation and Delivery Device-Related Effects on In Vitro Performance of Nasal Spray with Implication to Rational Product Specification Identification. Grmaš J; Stare K; Božič D; Injac R; Dreu R J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):230-246. PubMed ID: 28075184 [TBL] [Abstract][Full Text] [Related]
10. Prediction of pharmacokinetic studies outcome for locally acting nasal sprays by using different in vitro methods. Sibinovska N; Božič D; Bošković Ribarski M; Kristan K Int J Pharm; 2021 May; 601():120569. PubMed ID: 33812972 [TBL] [Abstract][Full Text] [Related]
11. Population and individual bioequivalence: lessons from real data and simulation studies. Zariffa NM; Patterson SD J Clin Pharmacol; 2001 Aug; 41(8):811-22. PubMed ID: 11504268 [TBL] [Abstract][Full Text] [Related]
12. A multivariate test for population bioequivalence. Chervoneva I; Hyslop T; Hauck WW Stat Med; 2007 Mar; 26(6):1208-23. PubMed ID: 16810712 [TBL] [Abstract][Full Text] [Related]
13. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective. Liu Q; Absar M; Saluja B; Guo C; Chowdhury B; Lionberger R; Conner DP; Li BV AAPS J; 2019 Jan; 21(2):14. PubMed ID: 30617594 [TBL] [Abstract][Full Text] [Related]
14. Automated actuation of nasal spray products: effect of hand-related variability on the in vitro performance of Flonase nasal spray. Doughty DV; Hsu W; Dalby RN Drug Dev Ind Pharm; 2014 Jun; 40(6):711-8. PubMed ID: 23594299 [TBL] [Abstract][Full Text] [Related]
15. Equivalence Testing of Complex Particle Size Distribution Profiles Based on Earth Mover's Distance. Hu M; Jiang X; Absar M; Choi S; Kozak D; Shen M; Weng YT; Zhao L; Lionberger R AAPS J; 2018 Apr; 20(3):62. PubMed ID: 29651627 [TBL] [Abstract][Full Text] [Related]
16. Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical-driven balance of population average and variability. Soufsaf S; Nekka F; Li J CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):482-493. PubMed ID: 35303757 [TBL] [Abstract][Full Text] [Related]
17. Prescribability and switchability of highly variable drugs and drug products. Midha KK; Rawson MJ; Hubbard JW J Control Release; 1999 Nov; 62(1-2):33-40. PubMed ID: 10518632 [TBL] [Abstract][Full Text] [Related]
18. PhRMA perspective on population and individual bioequivalence. Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305 [TBL] [Abstract][Full Text] [Related]
19. A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations. Joukhadar C; Schenk B; Kaehler ST; Kollenz CJ; Bauer P; Müller M; Eichler HG Eur J Clin Pharmacol; 2003 Nov; 59(8-9):631-6. PubMed ID: 14564429 [TBL] [Abstract][Full Text] [Related]
20. Assessment of the influence factors on in vitro testing of nasal sprays using Box-Behnken experimental design. Guo C; Stine KJ; Kauffman JF; Doub WH Eur J Pharm Sci; 2008 Dec; 35(5):417-26. PubMed ID: 18832029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]